

Neurophysiological and Biomolecular Effects of Atogepant in Episodic Migraine

NCT06882122

Status	RECRUITING
Sponsor	IRCCS National Neurological Institute "C. Mondino" Foundation
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (5)

- Individuals aged between 18 and 70;
- Diagnosis of episodic migraine according to ICHD-3 criteria;
- Monthly migraine days between 8 and 14 (high-frequency episodic migraine pattern) in the 3 months before screening;
- Individuals naïve to CGRP-targeted treatments;
- No more than one ongoing migraine preventive treatment with a stable dose for at least 3 months.

Exclusion (7)

- Contraindications to atogepant;
- History of serious psychiatric conditions;
- Diagnosis of other primary or secondary headaches (only sporadic tension-type headache is allowed);
- Medical conditions considered clinically significant by the investigator;
- Chronic pain conditions that need chronic treatment;
- ... and 2 more (see full listing online)

Locations (1 total)

Headache Science & Neurorehabilitation Center, Pavia, PAVIA, Italy